W-SUDs for COVID-19
Woebot for Substance Use Disorders During COVID-19
Sponsor: National Institute on Drug Abuse (NIDA)
Listed as NCT04460027, this PHASE1 trial focuses on Alcohol Use Disorder and Substance Use Disorders and remains completed. Sponsored by National Institute on Drug Abuse (NIDA), it has been updated 8 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1
-
May 2021 — Dec 2022 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
Jan 2021 — May 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE1
Phase: NA → PHASE1
-
Aug 2020 — Sep 2020 [monthly]
Recruiting NA
First recorded
Jun 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute on Drug Abuse (NIDA)
- Stanford University
- Woebot Health
For direct contact, visit the study record on ClinicalTrials.gov .